New shot for hemophilia shows early promise in small study
NCT ID NCT05493631
First seen Nov 28, 2025 · Last updated May 25, 2026 · Updated 26 times
Summary
This early-stage study tested a new drug called MG1113 in 15 men with severe hemophilia A or B. The goal was to check if the drug is safe and how it works in the body. Participants received multiple doses under the skin. The study is complete, and results will help decide if larger trials should move forward.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GC Biopharma Corp.
Yongin-si, Gyeonggi-do, 16924, South Korea
Conditions
Explore the condition pages connected to this study.